Correlation Between Sk Biopharmaceutica and OliX PharmaceuticalsI

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sk Biopharmaceutica and OliX PharmaceuticalsI at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sk Biopharmaceutica and OliX PharmaceuticalsI into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sk Biopharmaceuticals Co and OliX PharmaceuticalsInc, you can compare the effects of market volatilities on Sk Biopharmaceutica and OliX PharmaceuticalsI and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sk Biopharmaceutica with a short position of OliX PharmaceuticalsI. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sk Biopharmaceutica and OliX PharmaceuticalsI.

Diversification Opportunities for Sk Biopharmaceutica and OliX PharmaceuticalsI

0.66
  Correlation Coefficient

Poor diversification

The 3 months correlation between 326030 and OliX is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding Sk Biopharmaceuticals Co and OliX PharmaceuticalsInc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on OliX PharmaceuticalsInc and Sk Biopharmaceutica is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sk Biopharmaceuticals Co are associated (or correlated) with OliX PharmaceuticalsI. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of OliX PharmaceuticalsInc has no effect on the direction of Sk Biopharmaceutica i.e., Sk Biopharmaceutica and OliX PharmaceuticalsI go up and down completely randomly.

Pair Corralation between Sk Biopharmaceutica and OliX PharmaceuticalsI

Assuming the 90 days trading horizon Sk Biopharmaceutica is expected to generate 4.09 times less return on investment than OliX PharmaceuticalsI. But when comparing it to its historical volatility, Sk Biopharmaceuticals Co is 2.16 times less risky than OliX PharmaceuticalsI. It trades about 0.03 of its potential returns per unit of risk. OliX PharmaceuticalsInc is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  1,429,000  in OliX PharmaceuticalsInc on September 20, 2024 and sell it today you would earn a total of  533,000  from holding OliX PharmaceuticalsInc or generate 37.3% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy99.59%
ValuesDaily Returns

Sk Biopharmaceuticals Co  vs.  OliX PharmaceuticalsInc

 Performance 
       Timeline  
Sk Biopharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sk Biopharmaceuticals Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Sk Biopharmaceutica is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
OliX PharmaceuticalsInc 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in OliX PharmaceuticalsInc are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, OliX PharmaceuticalsI sustained solid returns over the last few months and may actually be approaching a breakup point.

Sk Biopharmaceutica and OliX PharmaceuticalsI Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sk Biopharmaceutica and OliX PharmaceuticalsI

The main advantage of trading using opposite Sk Biopharmaceutica and OliX PharmaceuticalsI positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sk Biopharmaceutica position performs unexpectedly, OliX PharmaceuticalsI can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OliX PharmaceuticalsI will offset losses from the drop in OliX PharmaceuticalsI's long position.
The idea behind Sk Biopharmaceuticals Co and OliX PharmaceuticalsInc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Other Complementary Tools

Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Fundamental Analysis
View fundamental data based on most recent published financial statements